Cidara Therapeutics CDTX Stock
Cidara Therapeutics Price Chart
Cidara Therapeutics CDTX Financial and Trading Overview
| Cidara Therapeutics stock price | 221.38 USD |
| Previous Close | 221.38 USD |
| Open | 221.32 USD |
| Bid | 156.95 USD x 200 |
| Ask | 282 USD x 200 |
| Day's Range | 221.31 - 221.41 USD |
| 52 Week Range | 15.22 - 221.42 USD |
| Volume | 2.69M USD |
| Avg. Volume | 1.43M USD |
| Market Cap | 6.96B USD |
| Beta (5Y Monthly) | 1.526 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 221.5 USD |
CDTX Valuation Measures
| Enterprise Value | 6.54B USD |
| Trailing P/E | N/A |
| Forward P/E | -30.70215 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | |
| Price/Book (mrq) | 15.374679 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -40.945 |
Trading Information
Cidara Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.526 |
| 52-Week Change | 915.50% |
| S&P500 52-Week Change | 21.96% |
| 52 Week High | 221.42 USD |
| 52 Week Low | 15.22 USD |
| 50-Day Moving Average | 196.94 USD |
| 200-Day Moving Average | 89.05 USD |
CDTX Share Statistics
| Avg. Volume (3 month) | 1.43M USD |
| Avg. Daily Volume (10-Days) | 939.82K USD |
| Shares Outstanding | 31.45M |
| Float | 23.11M |
| Short Ratio | 1.34 |
| % Held by Insiders | 0.45% |
| % Held by Institutions | 103.88% |
| Shares Short | 2.02M |
| Short % of Float | 6.42% |
| Short % of Shares Outstanding | 6.41% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | September 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -29.35% |
| Return on Equity (ttm) | -68.69% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -131820000 USD |
| EBITDA | -159776992 USD |
| Net Income Avi to Common (ttm) | -184800000 USD |
| Diluted EPS (ttm) | -11.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 420.02M USD |
| Total Cash Per Share (mrq) | 13.36 USD |
| Total Debt (mrq) | 1.98M USD |
| Total Debt/Equity (mrq) | 0.47 USD |
| Current Ratio (mrq) | 4.62 |
| Book Value Per Share (mrq) | 14.399 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -132940000 USD |
| Levered Free Cash Flow (ttm) | -32148500 USD |
Profile of Cidara Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 6310 Nancy Ridge Drive |
| ZIP | 92121 |
| Phone | 858 752 6170 |
| Website | https://www.cidara.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 38 |
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Q&A For Cidara Therapeutics Stock
What is a current CDTX stock price?
Cidara Therapeutics CDTX stock price today per share is 221.38 USD.
How to purchase Cidara Therapeutics stock?
You can buy CDTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cidara Therapeutics?
The stock symbol or ticker of Cidara Therapeutics is CDTX.
Which industry does the Cidara Therapeutics company belong to?
The Cidara Therapeutics industry is Biotechnology.
How many shares does Cidara Therapeutics have in circulation?
The max supply of Cidara Therapeutics shares is 31.45M.
What is Cidara Therapeutics Price to Earnings Ratio (PE Ratio)?
Cidara Therapeutics PE Ratio is 0.00000000 now.
What was Cidara Therapeutics earnings per share over the trailing 12 months (TTM)?
Cidara Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Cidara Therapeutics company belong to?
The Cidara Therapeutics sector is Healthcare.
Cidara Therapeutics CDTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}